Fulcrum Therapeutics, Inc.(FULC)
Biotechnology
Rare Disease / Orphan Drug
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-02-04 | Gould Robert J Director | Sale | -15,000 | -3.09%469,864 | $10.87 | $163,089 | View SEC filing | |
| 2026-02-04 | Gould Robert J Director | Sale | -15,000 | -3.19%454,864 | $10.72 | $160,857 | View SEC filing | |
| 2026-01-06 | Gould Robert J Director | Sale | -15,000 | -3.09%469,864 | $11.87 | $178,089 | View SEC filing | |
| 2025-12-17 | Oltmans Curtis Gale Chief Legal Officer | Sale | -3,452 | -25.19%10,252 | $12.92 | $44,600 | View SEC filing | |
| 2025-12-10 | RA Capital Healthcare Fund LP 10% Owner | Sale | -4,175,139 | -40.82%6,053,960 | $13.98 | $58,377,021 | View SEC filing | |
| 2025-11-21 | Gould Robert J Director | Sale | -15,000 | -3.00%484,864 | $11.03 | $165,495 | View SEC filing | |
| 2025-05-09 | Tourangeau Greg Principal Accounting Officer | Sale | -498 | -3.42%14,062 | $5.06 | $2,520 | View SEC filing | |
| 2024-05-09 | Tourangeau Greg Principal Accounting Officer | Sale | -236 | -2.00%11,571 | $7.76 | $1,831 | View SEC filing | |
| 2024-03-08 | Tourangeau Greg Vice President, Finance | Sale | -4,884 | -29.26%11,807 | $11.72 | $57,219 | View SEC filing | |
| 2024-03-05 | Sapir Alex See Remarks | Purchase | +43,360 | +100.00%43,360 | $11.35 | $492,028 | View SEC filing | |
| 2023-05-11 | Tourangeau Greg Principal Accounting Officer | Sale | -210 | -1.30%15,992 | $3.31 | $695 | View SEC filing | |
| 2023-01-24 | RA Capital Healthcare Fund LP 10% Owner | Purchase | +1,923,076 | +19.85%11,609,704 | $13.00 | $24,999,988 | View SEC filing | |
| 2023-01-13 | Gould Robert J Interim President & CEO | Sale | -6,766 | -1.34%499,864 | $15.00 | $101,490 | View SEC filing | |
| 2023-01-06 | RA Capital Healthcare Fund LP 10% Owner | Purchase | +180,703 | +1.90%9,686,628 | $7.28 | $1,314,806 | View SEC filing | |
| 2022-12-29 | RA Capital Healthcare Fund LP 10% Owner | Purchase | +4,089 | +0.04%9,505,925 | $5.99 | $24,510 | View SEC filing | |
| 2022-12-21 | RA Capital Healthcare Fund LP 10% Owner | Purchase | +98,787 | +1.05%9,501,836 | $5.90 | $582,814 | View SEC filing | |
| 2022-12-16 | RA Capital Healthcare Fund LP 10% Owner | Purchase | +2,403,049 | +34.33%9,403,049 | $5.44 | $13,073,874 | View SEC filing | |
| 2022-06-08 | Gould Robert J Director | Sale | -71,435 | -12.36%506,630 | $8.09 | $577,895 | View SEC filing | |
| 2022-06-06 | Gould Robert J Director | Sale | -66,622 | -3.19%506,630 | $8.00 | $532,810 | View SEC filing | |
| 2022-04-11 | Gould Robert J Director | Sale | -5,631 | -1.10%506,630 | $24.02 | $135,228 | View SEC filing | |
| 2022-04-05 | Gould Robert J Director | Sale | -94,251 | -6.37%506,630 | $24.16 | $2,276,684 | View SEC filing | |
| 2021-08-12 | Moxham Christopher Chief Scientific Officer | Sale | -51,785 | -100.00%0 | $17.60 | $911,416 | View SEC filing | |
| 2021-08-12 | Stuart Bryan See Remarks | Sale | -60,000 | -100.00%0 | $20.42 | $1,225,000 | View SEC filing | |
| 2021-06-29 | Morabito Christopher Chief Medical Officer | Purchase | +1,100 | +100.00%1,100 | $9.16 | $10,076 | View SEC filing | |
| 2021-06-29 | Oltmans Curtis Gale SVP, General Counsel | Purchase | +1,088 | +100.00%1,088 | $9.01 | $9,803 | View SEC filing |
1-25 of 65